Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 108-114

  Picard, M ^a   Pham Dang, N ^a   D'Incan, M ^a   Mansard, S ^a   Dechelotte, P ^a   Pereira, B ^a   Mondie, J M ^a   Barthelemy, I ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE DISSECTION; SENTINEL LYMPH NODE METASTASIS; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 84904988431     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12939     Document Type: Article

References (18)

1. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
2. Safaee Ardekani G, Jafarnejad SM, Khosravi S, et al,. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Br J Dermatol 2013; 169: 320-8.
3. Bauer J, Büttner P, Murali R, et al,. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-51.
4. Lee J-H, Choi J-W, Kim Y-S,. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-84.
5. Yancovitz M, Litterman A, Yoon J, et al,. Intra- and inter-tumor heterogeneity of BRAF V600E mutations in primary and metastatic melanoma. PLOS ONE 2012; 7: e29336.
6. Lin J, Goto Y, Murata H, et al,. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer 2011; 104: 464-8.
7. Navin N, Kendall J, Troge J, et al,. Tumour evolution inferred by single-cell sequencing. Nature 2011; 472: 90-4.
8. Parsons BL,. Many different tumor types have polyclonal tumor origin: evidence and implications. Mutat Res 2008; 659: 232-47.
9. Balch CM, Gershenwald JE, Soong S-J, et al,. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
10. V600 mutations in melanoma patients after resection of metastatic lymph nodes. Ann Surg Oncol 2012; 19: 4314-21.
11. Safaee Ardekani G, Jafarnejad SM, Tan L, et al,. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLOS ONE 2012; 7: e47054.
12. Greene VR, Johnson MM, Grimm EA, Ellerhorst JA,. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 2009; 129: 1483-8.
13. Ekedahl H, Cirenajwis H, Harbst K, et al,. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. Br J Dermatol 2013; 169: 1049-55.
14. Parisi F, Micsinai M, Strino F, et al,. Integrated analysis of tumor samples sheds light on tumor heterogeneity. Yale J Biol Med 2012; 85: 347-61.
15. Curtin JA, Fridlyand J, Kageshita T, et al,. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
16. Liu W, Kelly JW, Trivett M, et al,. Distinct clinical and pathological features are associated with the BRAF (T1799A (V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127: 900-5.
17. Houben R, Becker JC, Kappel A, et al,. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 2004; 3: 6.
18. Sakaizawa K, Goto Y, Kiniwa Y, et al,. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer 2012; 106: 939-46.